Medication Contraindications for Robaxin (Methocarbamol)
Methocarbamol is absolutely contraindicated in patients with known or suspected renal pathology and in those with hypersensitivity to methocarbamol or any injection components 1.
Absolute Contraindications
Renal Impairment
The FDA label explicitly states that Robaxin Injectable should not be administered to patients with known or suspected renal pathology 1. This contraindication exists because the injectable formulation contains polyethylene glycol 300 as a vehicle, which can theoretically increase pre-existing acidosis and urea retention in patients with renal impairment. While the amount present in recommended doses is within safety limits, the manufacturer maintains this contraindication out of caution 1.
Hypersensitivity
Methocarbamol is contraindicated in patients with known hypersensitivity to methocarbamol itself or to any components of the injection 1.
Critical Drug Interactions and Relative Contraindications
Myasthenia Gravis Patients on Pyridostigmine
Methocarbamol should not be used in patients with myasthenia gravis 2. The drug has been found to interfere with the effects of pyridostigmine bromide, which is essential for managing myasthenia gravis. Using methocarbamol in these patients could precipitate a myasthenic crisis by reducing the effectiveness of their anticholinesterase therapy.
CNS Depressants and Alcohol
While not an absolute contraindication, patients receiving methocarbamol should be strongly cautioned about combined effects with alcohol and other CNS depressants 1. A fatal case report documented the lethal interaction between methocarbamol and ethanol, where the combination led to severe CNS depression due to their interactive sedative-hypnotic properties 3. The blood methocarbamol concentration in this fatal case was 257 micrograms/mL with a blood ethanol of 135 mg/dL.
Important Clinical Considerations
Hepatic and Renal Dysfunction
Methocarbamol elimination is significantly impaired in patients with liver and kidney disease 2. While this may not be an absolute contraindication for oral formulations in mild-to-moderate hepatic impairment, extreme caution is warranted, and dose adjustments are necessary.
Pregnancy
The FDA label states that Robaxin Injectable should not be used in women who are or may become pregnant, particularly during early pregnancy, unless potential benefits clearly outweigh possible hazards 1. Very rare reports of fetal and congenital abnormalities following in utero exposure exist, though causality has not been definitively established.
Perioperative Management
According to the 2021 SPAQI consensus guidelines, methocarbamol should be held on the day of surgical procedures 2. This recommendation is based on its CNS depressant effects, potential for cardiovascular effects including bradycardia and hypotension, and interactions with anesthetic agents.
Common Pitfalls to Avoid
- Do not assume oral and injectable formulations have the same contraindications: The renal contraindication is specific to the injectable form due to polyethylene glycol content
- Do not overlook myasthenia gravis: Always screen for this condition before prescribing methocarbamol, as the interaction with pyridostigmine can be clinically significant
- Do not underestimate alcohol interactions: The combination can be fatal, not just sedating
- Do not use in activities requiring mental alertness: Methocarbamol may impair mental and physical abilities required for operating machinery or driving 1